Clinical Trial Update: Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating multiple doses of lesogaberan (AZD3355) added to proton pump inhibitor therapy in GERD patients with partial response; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Lesogaberan (lesogaberan)

Snippet

Sponsor: AstraZeneca | Conditions: Gastroesophageal Reflux Disease, Heartburn | Phase 2 | Status: COMPLETED | Results posted: 2011-04-25